Introduction {#sec1_1}
============

Ogilvie syndrome was first described by Sir Heneage Ogilvie in 1948. His original case report presented 2 patients with colonic obstruction without any diagnosed colonic pathology. Upon exploratory laparotomy, these patients were found to have areas of carcinoma unrelated to the colon \[[@B1]\]. It was hypothesized that the carcinoma was responsible for disrupting the balance between the parasympathetic and sympathetic nervous systems, leading to colonic pseudo-obstruction. Maloney and Vargas \[[@B2]\] showed success following treatment with neostigmine, providing further evidence for pseudo-obstruction. Ogilvie syndrome has been expanded to include other causes of pseudo-obstruction, as found in postoperative patients or those with metabolic anomalies \[[@B3]\].

Case Report {#sec1_2}
===========

We present the case of a 48-year-old male with a past medical history of diabetes mellitus, hypertension, hypercholesterolemia, and intellectual disability who arrived at the ER from a nursing home with abdominal distention 12 days following right total knee arthroplasty. He described progressive distention without pain, which had been progressing since the surgery. He reported having daily bowel movements during this period. The patient denied nausea, vomiting, fever, or chills.

The review of systems was unremarkable. The clinical exam showed vital signs that were within normal limits. Physical examination revealed gross distention of the abdomen, which was otherwise soft and nontender without rebound, guarding, or rigidity. Normal bowel sounds were present. Digital exam revealed soft brown stool in the rectal vault, and no masses or significant tenderness was appreciated. The remainder of the physical exam was essentially unremarkable. Laboratory results were also unremarkable (Table [1](#T1){ref-type="table"}). Roentography (Fig. [1](#f1){ref-type="fig"}) and CT (Fig. [2](#f2){ref-type="fig"}) of the abdomen revealed massive colonic dilatation from cecum to rectum without any observable masses or narrowings.

The patient was initially managed with trials of enemas at the nursing home for 2 days without improvement. Patient was kept NPO for that duration until it was decided to take the patient to the ER. In the ER, a CT of the abdomen was done, which showed markedly distended colon with fluid and gas extending to the rectum. The next day, the patient underwent flexible sigmoidoscopy. The patients' distention markedly improved, albeit for a finite amount of time. Eventually, the distention came back full force which led to the diagnosis of Ogilvie syndrome. That same day, measures to replete potassium were made. Six days later, he was given a trial of 2 mg neostigmine. He had 2 bowel movements following neostigmine infusion; however, the colonic distention did not resolve. A second trial of neostigmine was given the next day but with similar results, and the decision for surgical decompression and subtotal colectomy with colostomy was subsequently made with failure of conservative management. Intraoperatively the following day, the cecum was found to be 8 cm in diameter and the rectum was 15 cm in diameter. The total amount of resected colon was 160 cm. His postsurgical hospital course was uneventful. His diet was advanced successfully on postoperative day 3 with return of bowel function occurring on postoperative day 4. He had no further complications on subsequent office visits.

Discussion {#sec1_3}
==========

Conservative treatment has proven to be efficacious in the management of Ogilvie syndrome \[[@B4]\]. A study by Vanek and Al-Salti \[[@B5]\] showed a drastic decrease in mortality when colonic decompression was performed early in management especially with cecal diameters \>12 cm. As a greater understanding of the underlying mechanism was achieved, neostigmine emerged as an efficacious treatment for acute colonic pseudo-obstruction unresponsive to conservative management \[[@B6]\]. In 2 uncontrolled studies, intravenous neostigmine was effective in 80% of patients \[[@B7], [@B8]\]. Due to the risks associated with colonic distension and perforation, more invasive management is sought with failure after 2 trials of neostigmine or if neostigmine is contraindicated \[[@B2]\].

A review of 50 cases treated with colonoscopic decompression determined that it was 88% successful. The placement of a temporary decompression tube guided by the scope increased the efficacy \[[@B9]\]. In cases unresponsive to therapy, tube cecostomy is the preferred intervention. This is advantageous as it allows decompression of the large bowel and can be performed outside of the operating room in severely ill patients. Additionally, this method has proven efficacious in most reported cases \[[@B10], [@B11]\]. The most aggressive treatment, including the definitive treatment in our patient, involves subtotal or total colectomy with ileostomy.

While initially a promising treatment, percutaneous tube cecostomy quickly went under the scrutiny of critics. Wound infection, cecal fistula, and intraperitoneal leakage were commonly reported complications following placement \[[@B12]\]. A 1995 review of tube cecostomies used for the treatment of mechanical and pseudo-obstruction of the colon showed high complication rates. In a review of 67 patients, 45% had minor complications following placement of a tube cecostomy, including infection, occlusion, and premature dislodgment \[[@B11]\]. However, reoperation was not required in any of these patients, demonstrating both the success of this method and the lack of severe complications. A 2015 study involving cancer patients with large bowel obstruction further supported the use of tube cecostomy. No cases of colonic perforation were reported, and catheter removal was possible in 6 of 9 patients with pseudo-obstruction. Only 1 case out of 27 resulted in severe complications, and those were successfully managed with replacement of the cecostomy tube and antibiotics \[[@B13]\].

Chudzinski et al. \[[@B14]\] suggested surgical resection with colostomy or percutaneous tube cecostomy as treatment following failure of medical management in the resolution of colonic pseudo-obstruction. The decision regarding total versus subtotal colectomy is made based on the extent of the dilation. This more invasive option is associated with increased morbidity and mortality, especially when the reversal is taken into consideration. According to a 2005 retrospective cohort study, reversal and closure of the colostomy stoma is associated with a 20% complication rate and 3% mortality, with age being the only significant risk factor. Complications included anastomotic leaks and infections \[[@B15]\].

Ogilvie syndrome, although better understood today than when Ogilvie first described the disease, is still shrouded in mystery. Imbalance between parasympathetic and sympathetic stimulation is at the root of the issue; however, the specific mechanism of action has yet to be revealed. The current management for colonic pseudo-obstruction without peritoneal signs and colonic diameter \<12 cm is 2 trials of neostigmine followed by endoscopic decompression and finally colostomy with failure and recurrence. However, colostomy is fraught with complications and significantly reduces a patient\'s quality of life. Percutaneous tube cecostomy was once considered the standard of care with success rates up to 95%. Complications related to the management of the stoma, infection, and dislodgement of the tube led to its loss in popularity. Recent studies have suggested that current methods have led to a reduction in serious complications without sacrificing the success of the treatment modality. It is our opinion that tube cecostomy should be revisited as an alternative to colostomy in the resolution of pseudo-obstruction of the colon refractory to a more conservative medical management.
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###### 

Laboratory results were essentially unremarkable

  ------------------------ ------
  Glucose, mg/dL           104
  BUN, mg/dL               21
  Creatinine, mg/dL        0.8
  Sodium, mmol/L           141
  Potassium, mmol/L        3.2
  Chloride, mmol/L         108
  CO2, mmol/L              27
  Anion Gap                6
  Calcium, mg/dL           8.7
  Total protein, g/dL      6.7
  Albumin, g/dL            3.5
  Bilirubin total, mg/dL   0.9
  ALK phosphatase, μ/L     66
  AST, μ/L                 16
  ALT, μ/L                 12
  WBC, k/μL                3.9
  RBC, m/μL                2.69
  Hemoglobin, g/dL         8.3
  Hematocrit               25.4
  MCV                      94
  MCH                      30.9
  MCHC                     32.7
  Platelets, k/μL          401
  RDW                      15
  ------------------------ ------
